{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bicknell B"],"funding":["private donor"],"pagination":["368"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12786582"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(1)"],"pubmed_abstract":["<b>Background</b>: Parkinson's disease (PD) involves progressive neurodegeneration with clinical or subclinical disturbance of the gut-brain axis, including altered gastrointestinal motility and enteric nervous system involvement. Clinical studies have reported gut microbiome alterations in PD, with shifts in taxa associated with inflammatory signalling and short-chain fatty acid (SCFA) metabolism. Photobiomodulation (PBM), a non-invasive light therapy, has been investigated as a potential adjunctive treatment for PD, with proposed effects on neural, metabolic, and immune pathways. We previously reported the five-year clinical outcomes in a PBM-treated Parkinson's disease case series. Here we report the five-year gut microbiome outcomes based on longitudinal samples collected from the same"],"journal":["Journal of clinical medicine"],"pubmed_title":["Five-Year Follow-Up of Photobiomodulation in Parkinson's Disease: A Case Series Exploring Clinical Stability and Microbiome Modulation."],"pmcid":["PMC12786582"],"funding_grant_id":["NA"],"pubmed_authors":["McLachlan C","Kiat H","Bicknell B","Liebert A"],"additional_accession":[]},"is_claimable":false,"name":"Five-Year Follow-Up of Photobiomodulation in Parkinson's Disease: A Case Series Exploring Clinical Stability and Microbiome Modulation.","description":"<b>Background</b>: Parkinson's disease (PD) involves progressive neurodegeneration with clinical or subclinical disturbance of the gut-brain axis, including altered gastrointestinal motility and enteric nervous system involvement. Clinical studies have reported gut microbiome alterations in PD, with shifts in taxa associated with inflammatory signalling and short-chain fatty acid (SCFA) metabolism. Photobiomodulation (PBM), a non-invasive light therapy, has been investigated as a potential adjunctive treatment for PD, with proposed effects on neural, metabolic, and immune pathways. We previously reported the five-year clinical outcomes in a PBM-treated Parkinson's disease case series. Here we report the five-year gut microbiome outcomes based on longitudinal samples collected from the same","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-09T03:09:34.501Z","creation":"2026-06-09T03:07:22.233Z"},"accession":"S-EPMC12786582","cross_references":{"pubmed":["41517622"],"doi":["10.3390/jcm15010368"]}}